NCT07294092 Ketamine and Propofol NeuroImaging
| NCT ID | NCT07294092 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Keith M Vogt |
| Condition | Anesthesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-04-10 |
| Primary Completion | 2028-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2026-04-10 with a primary completion date of 2028-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-visit which will collect MRI (pictures of the brain) and EEG (brain waves) data to determine changes in brain connectivity and brain activity for memory formation and pain perception while receiving the commonly-used anesthetic agents ketamine and propofol, both alone and in combination.
Eligibility Criteria
Inclusion Criteria: * Adults 18-59 years of age, who: * have none of the specific exclusion criteria * have a valid email address and valid phone number throughout the study * free from any non-MRI compatible implants Exclusion Criteria: * are pregnant or attempting to conceive * body mass index (BMI) \> 35 * significant memory impairment or hearing loss * sleep apnea * chronic pain or frequently taking pain medication * chronic medical conditions requiring treatment (hypertension, diabetes, high cholesterol) * neurologic disease, including seizures and tremor * psychiatric diagnoses, including anxiety, depression, panic, or PTSD * a history of any of these medical conditions: abnormal heartbeats (cardiac conduction abnormality or arrhythmia), liver or kidney disease, or significant lung disease * severe claustrophobia or intolerance of an MRI * have metal implants or non-removable metal piercings * having a history of adverse reaction to ketamine or propofol * daily alcohol or heavy alcohol use; history of alcohol abuse * current daily smoker * regular or recent marijuana use (including prescribed/medical marijuana) * illicit drug use, i.e., street drugs * regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids
Contact & Investigator
Keith M Vogt, MD, PhD
PRINCIPAL INVESTIGATOR
University of Pittsburgh
Frequently Asked Questions
Who can join the NCT07294092 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 59 Years, studying Anesthesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07294092 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07294092 currently recruiting?
Yes, NCT07294092 is actively recruiting participants. Contact the research team at kev18@pitt.edu for enrollment information.
Where is the NCT07294092 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT07294092 clinical trial?
NCT07294092 is sponsored by Keith M Vogt. The principal investigator is Keith M Vogt, MD, PhD at University of Pittsburgh. The trial plans to enroll 60 participants.